2 results
Approved WMOCompleted
Primary Objective*To assess the safety and tolerability of Patidegib Topical Gel, 2% inpatients who have completed PellePharm Study Pelle-926-201 or Pelle-926-301Secondary Objectives*To assess the efficacy of Patidegib Topical Gel, 2% in patients…
Approved WMOCompleted
Primary objectivesPhase ITo establish the safety and tolerability of fractionated intravenous (i.v.) administrations of 177Lu-3BP-227 in subjects with unresectable, locally advanced or metastatic cancers expressing NTSR1.Phase IITo estimate ORR of…